The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II trial of olaparib + pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) mutations: SWOG S2001.
 
Vincent Chung
Consulting or Advisory Role - Apeiron Biologics; Gritstone Bio; Ipsen; Westwood Bioscience
Speakers' Bureau - Celgene; Ipsen
Research Funding - Merck (Inst); Roche (Inst)
 
Katherine A Guthrie
No Relationships to Disclose
 
Michael J. Pishvaian
Stock and Other Ownership Interests - Perthera
Honoraria - Halozyme
Consulting or Advisory Role - ARMO BioSciences; AstraZeneca/MedImmune; Caris Life Sciences; Merck; Perthera; Rafael Pharmaceuticals; RenovoRx; Sirtex Medical
Research Funding - Abbvie (Inst); ARMO BioSciences (Inst); Bavarian Nordic (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Curegenix (Inst); FibroGen (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Regeneron (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Perthera patient matching algorithm; Use patent for veliparib and FOLFOX
Travel, Accommodations, Expenses - Merck; Perthera; Sirtex Medical
 
Andrew M. Lowy
Consulting or Advisory Role - Fount Therapeutics; Halozyme; HUYA Bioscience International; Merck; PFizer; Rafael Pharmaceuticals
Research Funding - Mitsubishi Tanabe Pharma; Syros Pharmaceuticals
Expert Testimony - Merck
Travel, Accommodations, Expenses - Pfizer
 
Elena Gabriela Chiorean
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Celgene; Eisai; Five Prime Therapeutics; Halozyme; Ipsen; Legend Biotech; Seagen; Vicus Therapeutics
Research Funding - AADi (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); FibroGen; Halozyme (Inst); Ignyta (Inst); Incyte (Inst); Lilly (Inst); MacroGenics (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Legend Biotech; Seagen
 
Mai T. Duong
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); AstraZeneca (I); Autem Medical (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene (I); CytomX Therapeutics; Debiopharm Group (I); Eisai (I); Exelixis/Ipsen (I); Flatiron Health (I); Genentech/Roche (I); Gilead Sciences (I); Incyte (I); Ipsen (I); Janssen; LAM Therapeutics (I); Lilly (I); Loxo; Merck; Minapharma (I); QED Therapeutics (I); RedHill Biopharma (I); Silenseed; Sillajen (I); SOBI; TheraBionic (I); twoXAR; Vector Health (I); Yiviva (I)
Research Funding - Acta Biologica (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); MabVax (Inst); Roche (Inst); Silenseed (Inst)
 
Philip Agop Philip
Honoraria - Array BioPharma; AstraZeneca; Bayer; Blueprint Medicines; Celgene; Ipsen; Merck; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Bayer; Celgene; Incyte; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals